Silexion Therapeutics Corp, a biopharmaceutical company, discovers and develops RNA interference (RNAi)-based cancer drugs and delivery systems to treat malignant solid tumors. The company engages in the treatment of solid tumors through its proprietary LODER delivery platform. Its products comprise SiG12D-LODER that has completed pre-clinical studies and an open label Phase I clinical trial for the treatment of pancreatic cancer; Prostate-LODER, which is in pre-clinical studies for the treatment of prostate cancer; and GBM-LODER that is in pre-clinical studies to target Glioblastoma Multiform, a malignant primary brain tumor. Silexion Therapeutics Corp has collaboration with Evonik Corporation for the development of an advanced siRNA formulation to enhance cancer treatment. The company was founded in 2008 and is headquartered in Jerusalem, Israel.
Frequently asked questions
What sector does Biomotion Sciences Warrant (SLXNW) operate in?
Biomotion Sciences Warrant belongs to the Other sector and operates in the industry.
What is Biomotion Sciences Warrant (SLXNW) current stock price?
As of the latest data, Biomotion Sciences Warrant stock price is $0.01, with a previous close of $0.01. Biomotion Sciences Warrant lost -$0.00 in the last trading session, representing a -41.41% loss.
What is Biomotion Sciences Warrant (SLXNW) current market capitalization?
Biomotion Sciences Warrant market cap is approximately 3.99 thousand.
What is Biomotion Sciences Warrant (SLXNW) EBITDA?
Biomotion Sciences Warrant EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) is -3.68 million.
Does Biomotion Sciences Warrant (SLXNW) pay dividends?
No. Biomotion Sciences Warrant does not pay a dividend.
What is Biomotion Sciences Warrant (SLXNW) beta (volatility) score?
Biomotion Sciences Warrant has a beta of -0.362, indicating lower volatility than the overall market.
